20 Jun Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed.